We are live on
!
Find out more
Protalix BioTherapeutics
PLX
PLX
77 hedge funds and large institutions have $30.9M invested in Protalix BioTherapeutics in 2025 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
63% less call options, than puts
Call options by funds: $99K | Put options by funds: $269K
Holders
77
Holding in Top 10
–
Calls
$99K
Puts
$269K
Top Buyers
| 1 | +$4.2M | |
| 2 | +$295K | |
| 3 | +$244K | |
| 4 |
MSFS
Main Street Financial Solutions
Newtown,
Pennsylvania
|
+$210K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$187K |
Top Sellers
| 1 | -$637K | |
| 2 | -$488K | |
| 3 | -$367K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$289K |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$175K |